HIV-seq Uncovers Distinct Gene Expression in Latent vs. Active HIV Cells

A significant scientific breakthrough published in *Nature Communications* introduces a novel single-cell RNA sequencing (scRNA-seq) technique called 'HIV-seq,' which has provided unprecedented insights into the distinct biological states of HIV-transcribing cells in individuals with active viremia versus those on suppressive antiretroviral therapy (ART). The study, which was published on March 3, 2026, addresses a critical challenge in HIV research: understanding how the virus persists in a latent state despite effective ART, contributing to viral rebound if treatment is interrupted. Traditional scRNA-seq methods have faced considerable limitations in studying HIV-infected cells, primarily due to their low frequency within the body and the nature of HIV transcripts, which are often not polyadenylated. This characteristic means standard techniques, designed to capture polyadenylated RNA, frequently overlook a significant portion of HIV genetic material, making it difficult to fully characterize the 'active reservoir cells' – those cells that continue to transcribe HIV RNA even during ART suppression. These active reservoir cells are crucial because they perpetuate chronic inflammation and are believed to be key drivers of viral rebound. To overcome these hurdles, researchers, including Julie Frouard, Xiaoyu Luo, Natalie Gill, Reuben Thomas, and Nadia Roan of Gladstone, along with collaborators from the San Francisco VA Medical Center and the University of Melbourne, developed HIV-seq. This innovative method enhances the capture and detection of HIV transcripts, including the non-polyadenylated ones, by incorporating custom-designed capture sequences that target multiple conserved regions of the HIV genome during the scRNA-seq workflow. By spiking in these sequences, HIV-seq significantly improved the ability to identify HIV RNA-positive (HIV RNA+) cells from people with HIV (PWH) by up to 44%. This technological advancement allowed for the most in-depth scRNA-seq analysis of HIV RNA+ cells reported to date, covering both viremic and ART-suppressed states. The application of HIV-seq to paired blood samples collected from the same individuals during both viremia and after ART suppression yielded profound findings. The study unequivocally demonstrated that HIV RNA+ cells during ART suppression exhibit transcriptional features that are distinctly different from those observed during active viremia. This is a critical revelation, suggesting that HIV RNA+ cells from viremic individuals should not be used as a proxy to understand how HIV persists in ART-suppressed PWH, a practice that may have skewed previous research. Specifically, the researchers found that while HIV RNA+ cells were predominantly enriched among T effector memory (Tem) cells in both viremic and ART-suppressed conditions, their molecular signatures diverged significantly. During viremia, HIV RNA+ cells displayed a cytotoxic signature, indicating an active immune response. In stark contrast, HIV RNA+ cells from ART-suppressed timepoints exhibited a distinct anti-inflammatory signature. This anti-inflammatory profile was characterized by elevated levels of transforming growth factor-beta (TGF-β) signaling and diminished interferon (IFN) signaling. These observed differences in gene expression, such as upregulation of SRRM1 in viremic cells (a modulator of HIV-1 splicing) and lower levels of RBL2 and RPS10 (genes implicated in silencing HIV transcription) compared to ART-suppressed cells, provide a detailed molecular map of how the virus behaves under different clinical conditions. The implications of these findings are far-reaching for the global effort to eradicate HIV. By precisely characterizing the transcriptional landscape of active reservoir cells, HIV-seq provides a powerful tool to better understand the mechanisms by which these cells persist during ART. This enhanced understanding is vital for the development of new therapeutic strategies aimed at targeting and ultimately eliminating the latent HIV reservoir, a prerequisite for achieving a functional cure. Strategies could include drugs designed to reactivate latent virus more effectively (shock and kill) or approaches to render these cells less capable of sustaining the virus. For an audience in India, where a substantial number of people live with HIV, this research holds immense importance. India faces a significant burden of HIV/AIDS, and advancements in understanding viral persistence directly impact future treatment paradigms, cure initiatives, and overall public health strategies. The ability to distinguish between active and suppressed HIV cellular states opens avenues for more precise diagnostics and personalized therapeutic interventions, potentially leading to better patient outcomes and a reduction in the long-term health complications associated with living with HIV, even under ART. This research signifies a step forward in the global scientific community's quest to move beyond lifelong ART towards a permanent solution for HIV. The study underscores the ongoing need for innovative scientific approaches to tackle complex viral diseases and highlights the potential of advanced sequencing technologies to unravel previously intractable biological mysteries.

Frequently Asked Questions

Read Full Story on Quick Digest